Press coverage about Vital Therapies (NASDAQ:VTL) has been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vital Therapies earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.6136306340487 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
VTL has been the topic of a number of research reports. BidaskClub upgraded Vital Therapies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. Zacks Investment Research cut Vital Therapies from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Finally, ValuEngine upgraded Vital Therapies from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 21st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Vital Therapies has a consensus rating of “Hold” and a consensus price target of $8.00.
Shares of Vital Therapies (NASDAQ VTL) remained flat at $$5.20 on Friday. 214,236 shares of the stock traded hands, compared to its average volume of 157,280. Vital Therapies has a one year low of $2.25 and a one year high of $6.50.
Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. During the same period in the prior year, the firm earned ($0.32) EPS. equities analysts expect that Vital Therapies will post -1.29 EPS for the current fiscal year.
In related news, Director Muneer A. Satter purchased 50,000 shares of the firm’s stock in a transaction dated Friday, September 8th. The shares were purchased at an average cost of $3.53 per share, for a total transaction of $176,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jean Jacques Bienaime purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The shares were bought at an average price of $4.00 per share, for a total transaction of $40,000.00. Following the completion of the transaction, the director now owns 65,119 shares of the company’s stock, valued at $260,476. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 190,000 shares of company stock worth $737,800. Company insiders own 32.60% of the company’s stock.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.